Summary of Efficacy Results at Wk 104
| Variable* | Secukinumab | ||
|---|---|---|---|
| 300 mg s.c. | 150 mg s.c. | 75 mg s.c. | |
| (N=100) | (N=100) | (N=99) | |
| ACR20 | 69.4 | 64.4 | 50.3 |
| ACR50 | 50.6 | 36.0 | 28.2 |
| ACR70 | 33.1 | 23.1 | 14.9 |
| aPASI 75 | 79.5 | 73.3 | 58.4 |
| aPASI 90 | 69.6 | 52.5 | 33.7 |
| SF-36 PCS, LS mean change from BL (SE) | 6.8 (0.85) | 5.0 (0.87) | 4.1 (0.91) |
| DAS28-CRP, LS mean change from BL (SE) | ?1.9 (0.12) | ?1.7 (0.12) | ?1.5 (0.13) |
| HAQ-DI, LS mean change from BL (SE) | ?0.58 (0.05) | ?0.48 (0.06) | ?0.27 (0.06) |
| bResolution of enthesitis | 71.5 | 61.8 | 68.4 |
| cResolution of dactylitis | 79.9 | 78.0 | 88.6 |
*% responders unless otherwise specified. aAssessed in pts with psoriasis affecting ≥3% body surface area at BL (300 mg: n=41; 150 mg: n=58; 75 mg: n=50). bAssessed in pts (n=56 [300 mg], 64 [150 mg] and 68 [75 mg]) with this symptom at BL. cAssessed in pts (n=46 [300 mg], 32 [150 mg] and 33 [75 mg]) with this symptom at BL. BL, baseline; DAS28-CRP, 28-joint disease activity score using C-reactive protein; HAQ-DI, health assessment questionnaire-disability index; LS, least squares; N, number of pts randomised; PASI, psoriasis area and severity index; SE, standard error; SF-36 PCS, short form-36 physical component summary.